Strong operational performance to continue into H2e and 2024e. EUHA conference and Q3e to support the case. BUY, TP DKK 360 (305) on +4% EPS, increased visibility, low valuation.

22 Sep 2023
The Real Deal, and more to come

Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
The Real Deal, and more to come
- Published:
22 Sep 2023 -
Author:
ABGSC Healthcare Research | Morten Larsen -
Pages:
14 -
Strong operational performance to continue into H2e and 2024e. EUHA conference and Q3e to support the case. BUY, TP DKK 360 (305) on +4% EPS, increased visibility, low valuation.